Please assess the completion status of the following clinical trial:

Trial Title: Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child up to 15 years of age who fulfilled the 1997 updating the American College of Rheumatology revised criteria for the classification of SLE and his or her renal biopsy reveals lupus nephritis class III or IV regarding to International Society of Nephrology/Renal Pathology Society revision on the classification of the lupus nephritis.~Exclusion Criteria:~* patient who has prior renal insufficiency due to chronic kidney disease other than lupus nephritis~* patient who has the history of cyclophosphamide hypersensitivity~* patient who has prior cyclophosphamide or mycophenolate mofetil administration within 6 months~* patient who is pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Low-dose intravenous cyclophosphamide (Type: EXPERIMENTAL): Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
- High-dose intravenous cyclophosphamide (Type: ACTIVE_COMPARATOR): High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).